Depigmentation Therapy and Chemical Leukoderma in Vitiligo

Conclusions

• Chemical and physical depigmentation can be a valid goal for selected vitiligo patients whose priority is uniformity rather than repigmentation.
• Patients considering depigmentation require careful counseling because once melanocytes are destroyed, the effect is generally permanent and may take months to achieve.
• Monobenzyl ether of hydroquinone is the main depigmenting agent discussed, but it is irritating and should never be used to treat hyperpigmentation or melasma.
• Depigmentation therapy can spread beyond the application site, so clinicians must start with small test areas and monitor for unintended reactions such as irritant or allergic contact dermatitis.
• Cryotherapy and laser-assisted depigmentation, especially with Q-switched Alexandrite and Nd:YAG lasers, are effective alternatives for difficult or patchy vitiligo.
• Chemical leukoderma is an important and often underrecognized cause of pigment loss from exposures such as hair dyes, phenols, detergents, rhododendrol, imiquimod, and some systemic or topical agents.
• Patients with vitiligo should be warned about high-risk products like PPD-containing hair dyes, henna, lightening creams, and other unregulated cosmetics that can worsen depigmentation.
• Imiquimod can cause reversible vitiligo-like depigmentation, so counseling about pigment loss should accompany its use, especially on genital skin.
• Recent and emerging vitiligo therapies do not eliminate the need for depigmentation options in patients with chronic unstable disease who continue to lose pigment despite treatment.
• Cultural context and individual body-image goals strongly influence treatment decisions, making patient-centered counseling essential in vitiligo care.